[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU1032701A - Deglycosylated env/cd4 complex and the use thereof for vaccination against hiv - Google Patents

Deglycosylated env/cd4 complex and the use thereof for vaccination against hiv

Info

Publication number
AU1032701A
AU1032701A AU10327/01A AU1032701A AU1032701A AU 1032701 A AU1032701 A AU 1032701A AU 10327/01 A AU10327/01 A AU 10327/01A AU 1032701 A AU1032701 A AU 1032701A AU 1032701 A AU1032701 A AU 1032701A
Authority
AU
Australia
Prior art keywords
deglycosylated
env
complex
against hiv
vaccination against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU10327/01A
Inventor
Florence Boudet
Michel Chevalier
Jean Dubayle
Raphaelle El Habib
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Aventis Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur SA filed Critical Aventis Pasteur SA
Publication of AU1032701A publication Critical patent/AU1032701A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU10327/01A 1999-10-25 2000-10-23 Deglycosylated env/cd4 complex and the use thereof for vaccination against hiv Abandoned AU1032701A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9913549 1999-10-25
FR9913549A FR2799974B1 (en) 1999-10-25 1999-10-25 DEGLYCOSYL PROTEIN ENV / CD4 COMPLEX AND USE THEREOF FOR VACCINATION AGAINST HIV
PCT/FR2000/002940 WO2001030814A1 (en) 1999-10-25 2000-10-23 Deglycosylated env/cd4 complex and the use thereof for vaccination against hiv

Publications (1)

Publication Number Publication Date
AU1032701A true AU1032701A (en) 2001-05-08

Family

ID=9551513

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10327/01A Abandoned AU1032701A (en) 1999-10-25 2000-10-23 Deglycosylated env/cd4 complex and the use thereof for vaccination against hiv

Country Status (3)

Country Link
AU (1) AU1032701A (en)
FR (1) FR2799974B1 (en)
WO (1) WO2001030814A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0308896A (en) 2002-05-07 2007-01-09 Chiron Corp hiv-cd4 envelope complex and hybrid
EP1784513A4 (en) 2004-06-08 2010-01-06 Novartis Vaccines & Diagnostic Fusion proteins comprising cd4 minimal modules and methods of use thereof
US8168194B2 (en) 2005-02-03 2012-05-01 Novartis Vaccines & Diagnostics, Inc. Fusion proteins comprising CD4 minimal modules and human immunodeficiency virus (HIV) Tat scaffold polypeptides that are capable of binding to the HIV envelope and exposing cryptic neutralization epitopes
CN107375919B (en) * 2009-03-27 2022-07-29 台湾地区“中央研究院” Methods and compositions for antiviral immunization
TWI537385B (en) 2010-11-04 2016-06-11 中央研究院 Methods for producing virus particles with simplified glycosylation of surface proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2091253A1 (en) * 1990-09-28 1992-03-29 Franco Celada Method for inhibiting the infectivity of human immunodeficiency virus
DK0699077T3 (en) * 1993-05-07 2002-01-21 Bio Merieux Inc Immunogelous HIV complexes

Also Published As

Publication number Publication date
FR2799974B1 (en) 2001-11-30
WO2001030814A1 (en) 2001-05-03
FR2799974A1 (en) 2001-04-27

Similar Documents

Publication Publication Date Title
AU2002241534A1 (en) Disposable aerosol generator system and methods for administering the aerosol
AU2001256184A1 (en) 6-aminoalkyl-dihydropyrimidines and the use thereof as medicaments against viraldiseases
AU2150900A (en) Hiv-specific t-cell induction
AU4012100A (en) Pseudotyped lentiviral vectors and uses thereof
AU3614901A (en) Polyorganosilsesquioxane and process for preparing the same
AU5010700A (en) Pizza delivery bags and methods
AP2001002300A0 (en) Hiv immunogenic compositions and methods
MXPA02001891A (en) A vaccine composition and method of using the same.
AUPR183100A0 (en) Wood products and processes for the preparation thereof
GB9826069D0 (en) HIV vaccine
AU3159000A (en) Phosphorus-comprising materials, their preparation and use
AU5117400A (en) Tip structures, devices on their basis, and methods for their preparation
AU6635800A (en) Pyridomorphinans, thienomoprhinans and use thereof
AU3366899A (en) Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
AU4443200A (en) Secure wap transactions using voice based authentication
ZA200203294B (en) N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them.
AU1032701A (en) Deglycosylated env/cd4 complex and the use thereof for vaccination against hiv
AU2002213882A1 (en) Attenuated hiv strains and use thereof
AU4472801A (en) Inactivated japanese B encephalitis vaccine and process for producing the same
AU1912501A (en) Water-soluble powders for oral solution and use thereof
GB0025341D0 (en) Applicator e.g for shaving preparations and the like
AU2002234165A1 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
AU4333600A (en) Water-soluble trioxanes as potent and safe antimalarial agents
AU2001268653A1 (en) Combination hiv therapy including camptothecin
AU2001252671A1 (en) Pyridobenzodiazine derivatives and processes for the preparation thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase